Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.92 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | PDE4A | P27815 | 1/20 | 0.58 |
| ▸ | USP2 | O75604 | 1/20 | 0.52 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | TOP1 | P11387 | 1/20 | 0.38 |
| ▸ | MGAM | O43451 | 2/20 | 0.35 |
| ▸ | SI | P14410 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mannitol SCHEMBL1406343 | 1.00 | LMNA (1.00) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Mannitol SCHEMBL2477078 | 1.00 | LMNA (1.00) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Sorbitol SCHEMBL763 | 1.00 | LMNA (1.00) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Mannitol SCHEMBL20594083 | 1.00 | LMNA (1.00) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Mannitol SCHEMBL20594082 | 1.00 | LMNA (1.00) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Mannitol SCHEMBL23066399 | 1.00 | LMNA (1.00) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Mannitol SCHEMBL13187369 | 1.00 | LMNA (1.00) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Mannitol SCHEMBL21837180 | 1.00 | LMNA (1.00) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Mannitol SCHEMBL20567656 | 1.00 | LMNA (1.00) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Mannitol SCHEMBL12455929 | 1.00 | LMNA (1.00) | LMNAL3MBTL1TDP1KDM4EPDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200277578-A1 | HETERO-TRANSGLYCOSYLASE AND USES THEREOF | BASF SE (DE) | 2020-09-03 | — | — | US | disclosed |
| US-10647965-B2 | Hetero-transglycosylase and uses thereof | BASF SE (DE) | 2020-05-12 | — | — | US | disclosed |
| EP-3217952-B1 | AMINO ACID DERIVATIVES AND THEIR USES | JOHNSON & JOHNSON CONSUMER INC (US) | 2019-02-20 | — | — | EP | disclosed |
| US-20190002849-A1 | HETERO-TRANSGLYCOSYLASE AND USES THEREOF | THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (GB) | 2019-01-03 | — | — | US | disclosed |
| US-10093907-B2 | Hetero-transglycosylase and uses thereof | BASF SE (DE) | 2018-10-09 | — | — | US | disclosed |
| EP-3049517-B1 | HETERO-TRANSGLYCOSYLASE AND USES THEREOF | BAYER CROPSCIENCE NV (BE) | 2018-04-11 | — | — | EP | disclosed |
| US-20170253608-A1 | Method for Preparing Anhydrosugar Alcohol Using Two-Step Hydrothermal Reaction | SK INNOVATION CO., LTD. (KR) | 2017-09-07 | — | — | US | disclosed |
| US-20170253608-A1 | Method for Preparing Anhydrosugar Alcohol Using Two-Step Hydrothermal Reaction | SK INNOVATION CO., LTD. (KR) | 2017-09-07 | — | — | US | disclosed |
| US-20160230150-A1 | HETERO-TRANSGLYCOSYLASE AND USES THEREOF | BASF SE (DE) | 2016-08-11 | — | — | US | disclosed |
| EP-3049517-A1 | HETERO-TRANSGLYCOSYLASE AND USES THEREOF | Bayer CropScience NV (BE) | 2016-08-03 | — | — | EP | disclosed |
| US-9249108-B2 | Multicomponent system of rosuvastatin calcium salt and sorbitol | BASF SE (DE) | 2016-02-02 | — | — | US | disclosed |
| US-9249108-B2 | Multicomponent system of rosuvastatin calcium salt and sorbitol | BASF SE (DE) | 2016-02-02 | — | — | US | disclosed |
| WO-2015044209-A1 | HETERO-TRANSGLYCOSYLASE AND USES THEREOF | BAYER CROPSCIENCE NV (BE) | 2015-04-02 | — | — | WO | disclosed |
| US-20130237553-A1 | MULTICOMPONENT SYSTEM OF RESUVASTATIN CALCIUM SALT AND SORBITOL | BASF SE (DE) | 2013-09-12 | — | — | US | disclosed |
| US-20130237553-A1 | MULTICOMPONENT SYSTEM OF RESUVASTATIN CALCIUM SALT AND SORBITOL | BASF SE (DE) | 2013-09-12 | — | — | US | disclosed |
| CN-101959516-B | Combination therapy comprising quinoxaline PI3K alpha inhibitors for the treatment of cancer | EXELIXIS INC | 2013-05-08 | — | — | CN | disclosed |
| US-7999006-B2 | Anticancer agents; mitogen-activated protein kinases (MEK) | EXELIXIS, INC. (US) | 2011-08-16 | — | — | US | disclosed |
| CN-101959516-A | Combination therapy comprising quinoxaline PI3K alpha inhibitors for the treatment of cancer | EXELIXIS INC | 2011-01-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170253608-A1 | Method for Preparing Anhydrosugar Alcohol Using Two-Step Hydrothermal Reaction | ADH1C, ADH1A, OGT | LMNA 4818/4885L3MBTL1 4694/4885TDP1 4628/4885 |
| US-20130237553-A1 | MULTICOMPONENT SYSTEM OF RESUVASTATIN CALCIUM SALT AND SORBITOL | SLC5A6, SOST, TRPV6 | LMNA 1250/4885L3MBTL1 4117/4885TDP1 2553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.